All News
Filter News
Found 809,040 articles
-
Taro to Release Second Quarter Results on October 27, 2022
10/24/2022
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2022, after the close of market on Thursday, October 27, 2022.
-
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022
10/24/2022
Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens.
-
Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3
10/24/2022
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.
-
PaxMedica Appoints Stefan Schwabe MD, PhD as Chief Medical Officer
10/24/2022
PaxMedica, Inc. (Nasdaq: PXMD), a clinical-stage biopharmaceutical company focused on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms such as autism spectrum disorder (“ASD”), today announced the appointment of Dr. Stefan Schwabe MD, PhD as Chief Medical Officer.
-
Brainlab Enters Cooperation with the German Society for Orthopedics and Orthopedic Surgery (DGOOC)
10/24/2022
Brainlab, a digital medical technology company, and the German Society for Orthopedics and Orthopedic Surgery (DGOOC) will work together in the field of data privacy-compliant registry solutions.
-
Delcath Systems to Host Third Quarter 2022 Results
10/24/2022
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2022.
-
PharmAbcine to participate in Jefferies 2022 London Healthcare Conference
10/24/2022
PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited at upcoming Jefferies 2022 London Healthcare Conference.
-
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
10/24/2022
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that clinical and preclinical data from its virology portfolio will be featured in four poster presentations, including two late breaker presentations, at the upcoming American Association for the Study of Liver Diseases (AASLD).
-
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
10/24/2022
Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.
-
BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022
10/24/2022
BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract characterizing the hospitalization burden of patients with cirrhosis and ascites and receiving treatment via paracentesis has been selected for presentation at The Liver Meeting 2022.
-
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
10/24/2022
Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting.
-
Singular Genomics to Report Third Quarter 2022 Financial Results on November 7, 2022
10/24/2022
Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022.
-
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022
10/24/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany.
-
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2022 Financial Results
10/24/2022
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2022 at 5:00 PM ET to report its third quarter 2022 financial results and provide a corporate update.
-
KaliVir Immunotherapeutics to Present at 14th International Oncolytic Virotherapy Conference (IOVC)
10/24/2022
KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announced that Dr. Stephen Thorne, Co-Founder and CSO, will present data on its product candidate VET3-TGI at the 14th International Oncolytic Virotherapy Conference (IOVC), taking place October 23-26, 2022, in Karuizawa, Nagano, Japan.
-
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
10/24/2022
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its third quarter financial results on Thursday, November 3, 2022.
-
Englewood Health Achieves Highest Possible Quality Rating for Valve Replacement Procedure
10/24/2022
Englewood Health has been recognized by The Society of Thoracic Surgeons with a 3-star rating—the highest possible quality rating—for transcatheter aortic valve replacement (TAVR).
-
Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022
10/24/2022
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on October 26, 2022.
-
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
10/24/2022
Ardelyx, Inc. (Nasdaq: ARDX) today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.
-
Vicarious Surgical to Report Third Quarter 2022 Financial Results on November 7, 2022
10/24/2022
Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the third quarter 2022 after the market closes on Monday, November 7, 2022.